C.R. Bard Stock To Go Ex-dividend Tomorrow (BCR)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- The ex-dividend date for C.R. Bard (NYSE: BCR) is tomorrow, April 25, 2013. Owners of shares as of market close today will be eligible for a dividend of 20 cents per share. At a price of $98.92 as of 9:35 a.m. ET, the dividend yield is 0.8%.

The average volume for C.R. Bard has been 637,200 shares per day over the past 30 days. C.R. Bard has a market cap of $8.08 billion and is part of the health care sector and health services industry. Shares are up 1.4% year to date as of the close of trading on Tuesday.

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company has a P/E ratio of 15.9, below the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates C.R. Bard as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, increase in net income, notable return on equity and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full C.R. Bard Ratings Report.

See our dividend calendar or top-yielding stocks list.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

EY's Greene Sees More Med Tech, CRO Deals Ahead

Deals of the Week: Waiting for Clarity

Merger Buzz Drives Akorn to Top of Health Chart in April

Deals of the Week: Reason for Optimism

Good Medicine Makes for 3 Good Charts